Clinical Trial Detail

NCT ID NCT03310541
Title AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Memorial Sloan Kettering Cancer Center
Indications

Advanced Solid Tumor

Therapies

Capivasertib

Capivasertib + Enzalutamide

Capivasertib + Fulvestrant

Age Groups: senior adult

Additional content available in CKB BOOST